Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2016
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza virus vaccine
- Indications Influenza A virus H5N1 subtype; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Jan 2014 Status changed from active, no longer recruiting to completed ClinicalTrials.gov record.
- 26 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 May 2013 Planned number of patients changed from 124 to 126 as reported by ClinicalTrials.gov.